IPOs/The Nasdaq Global Select Market/2026/TRex Bio, Inc.

TRex Bio, Inc. TRXB

TRex Bio, Inc. (TRXB) priced its IPO on The Nasdaq Global Select Market on October 9, 2026 at $14.00 a share. Clinical-stage biopharmaceutical company focused on tissue Treg biology for discovery and development of immunoregulatory medicines for autoimmune and inflammatory diseases. Based in South San Francisco, CA.

Registered
Priced
TradingNot yet
Offer price
$14.00
Raised
Not given
Shares offered
8,333,334 shares
Lock-up
180 days
See the prospectus →

The company

TRex Bio, Inc. is a clinical-stage biopharmaceutical company focused on tissue Treg biology for discovery and development of immunoregulatory medicines for autoimmune and inflammatory diseases. It is based in South San Francisco, CA, and sold 8,333,334 shares at $14.00 per share.

The proceeds will advance clinical development of TRB-061, advance clinical development of TRB-071, and fund working capital and other general corporate purposes. Existing shareholders hold the company after the offer.

Where the money goes

advance clinical development of TRB-061
advance clinical development of TRB-071
working capital and other general corporate purposes

Revenue and results

Revenue, year ended December 31, 2024$39,108
Revenue, year ended December 31, 2025$—
Revenue, six months ended June 30, 2025$—
Revenue, six months ended June 30, 2026$—
Net result, year ended December 31, 2024$3,144 loss
Net result, year ended December 31, 2025$34,806 loss
Net result, six months ended June 30, 2025$17,722 loss
Net result, six months ended June 30, 2026$29,308 loss

The risks it lists first

Limited operating history and no products approved for commercial sale
Will require substantial additional financing to achieve goals
Raising additional capital may cause dilution to stockholders